• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Forma Therapeutics Holdings Inc.

    2/10/22 8:11:45 AM ET
    $FMTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FMTX alert in real time by email
    SC 13G 1 tv0929-formatherapeuticshold.htm SCHEDULE 13G formatherapeuticsholdingsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    Name of issuer:  Forma Therapeutics Holdings Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  34633R104

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  34633R104

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    24,204

    7.  SOLE DISPOSITIVE POWER

    2,819,642

    8.  SHARED DISPOSITIVE POWER

    41,011

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,860,653

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.03%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Forma Therapeutics Holdings Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    300 North Beacon Street, Suite 501
    Watertown, MA 02472

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    34633R104

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $FMTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FMTX

    DatePrice TargetRatingAnalyst
    6/13/2022$46.00 → $21.00Overweight
    Cantor Fitzgerald
    11/12/2021$54.00 → $40.00Outperform
    SVB Leerink
    8/17/2021$55.00 → $53.00Buy
    HC Wainwright & Co.
    8/2/2021$58.00Buy
    Craig Hallum
    More analyst ratings

    $FMTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Forma Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

      Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that its Board of Directors granted to Agustín Melián, M.D. and Linea Aspesi non-qualified stock options of 118,000 and 59,000 shares, respectively, of its common stock pursuant to Inducement Non-Qualified Stock Option Agreements (the "Stock Options") and 79,000 and 39,000 restricted stock units, respectively, pursuant to Inducement Restricted Stock Unit Agreements (the "RSUs," and together with the Stock Options, the "Inducement Grants"). On June 30, 2022, Forma announced the appointment

      7/12/22 7:05:00 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer

      Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of Ifeyinwa (Ify) Osunkwo, MD, MPH, to the executive leadership team as the company's inaugural chief patient officer and senior vice president. In this role, Dr. Osunkwo will be responsible for realizing Forma's vision to transform the lives of patients by improving access and care through partnerships with global patient and community stakeholders. She will join Forma in the first quarter of 2022. "This appointment of a chief patient officer boldly represents our commitment to advancing both patient access and care a

      11/30/21 7:05:00 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer

      Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of John E. Bishop, Ph.D., to the leadership team as senior vice president and chief technology officer. In this role, Dr. Bishop will lead chemistry, manufacturing and control (CMC)-related functions and quality, encompassing Forma's early pipeline through commercial product. "We are fortunate to welcome John to Forma at this pivotal time in Forma's history," said Frank Lee, chief executive officer of Forma. "John's extensive expertise in small-molecule pharmaceuticals and proven track record as a leader will help to e

      6/14/21 7:05:00 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FMTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the Disease

      The "Believe it!" Campaign Will be Featured on TV Networks and Radio Stations Across the U.S., Driving Viewers to SCDBelieveIT.org The Sickle Cell Disease Association of America, Inc. (SCDAA), in partnership with Forma Therapeutics, Inc. (NASDAQ:FMTX) today announced that they have joined forces to create a public service announcement (PSA) to drive awareness and advance meaningful understanding of sickle cell disease (SCD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220930005106/en/ SCD occurs in one in every 365 Black Americans and affects an estimated 100,000 individuals in the U.S. 1 alone, according to the Centers for D

      9/30/22 9:00:00 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders

      Novo Nordisk and Forma Therapeutics, Holdings Inc. (NASDAQ:FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220901005393/en/ The acquisition of Forma Therapeutics, including its lead development candidate, etavopivat, is aligned with Novo Nordisk's strategy t

      9/1/22 8:00:00 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

      Announced analyses from Phase I study of etavopivat in sickle cell disease indicated reduction of reported pain-related adverse events, supporting potential to reduce vaso-occlusive crises Recently entered into an exclusive license agreement with Rigel Pharmaceuticals, Inc. for olutasidenib, a mutant IDH1 inhibitor for the potential treatment of relapsed or refractory acute myeloid leukemia Highlighted progress across portfolio at inaugural Research and Development (R&D) Day Appointed new members of Executive Team to prepare for growth in late-stage clinical development and commercialization Cash balance of $395.9 million positions company with runway through the third quarter of 2024

      8/5/22 7:00:00 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FMTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Forma Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)

      2/14/23 8:34:06 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Forma Therapeutics Holdings Inc. (Amendment)

      SC 13D/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)

      10/14/22 4:03:32 PM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Forma Therapeutics Holdings Inc. (Amendment)

      SC 13D/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)

      9/2/22 4:30:10 PM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on Forma Therapeutics with a new price target

      Cantor Fitzgerald resumed coverage of Forma Therapeutics with a rating of Overweight and set a new price target of $21.00 from $46.00 previously

      6/13/22 7:18:38 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Forma Therapeutics Hldgs with a new price target

      SVB Leerink reiterated coverage of Forma Therapeutics Hldgs with a rating of Outperform and set a new price target of $40.00 from $54.00 previously

      11/12/21 1:07:48 PM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Forma Therapeutics Hldgs with a new price target

      HC Wainwright & Co. reiterated coverage of Forma Therapeutics Hldgs with a rating of Buy and set a new price target of $53.00 from $55.00 previously

      8/17/21 6:25:41 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FMTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Lesser Brian Andrew closing all direct ownership in the company

      4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)

      10/14/22 4:07:40 PM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Potts Jeannette closing all direct ownership in the company

      4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)

      10/14/22 4:07:33 PM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Frederick Wayne A.I. closing all direct ownership in the company

      4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)

      10/14/22 4:07:15 PM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FMTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Forma Therapeutics Holdings Inc.

      15-12G - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)

      10/24/22 11:22:28 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Forma Therapeutics Holdings Inc.

      EFFECT - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)

      10/18/22 12:15:07 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Forma Therapeutics Holdings Inc.

      S-8 POS - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)

      10/14/22 9:27:29 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FMTX
    Financials

    Live finance-specific insights

    See more
    • Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders

      Novo Nordisk and Forma Therapeutics, Holdings Inc. (NASDAQ:FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220901005393/en/ The acquisition of Forma Therapeutics, including its lead development candidate, etavopivat, is aligned with Novo Nordisk's strategy t

      9/1/22 8:00:00 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

      Announced analyses from Phase I study of etavopivat in sickle cell disease indicated reduction of reported pain-related adverse events, supporting potential to reduce vaso-occlusive crises Recently entered into an exclusive license agreement with Rigel Pharmaceuticals, Inc. for olutasidenib, a mutant IDH1 inhibitor for the potential treatment of relapsed or refractory acute myeloid leukemia Highlighted progress across portfolio at inaugural Research and Development (R&D) Day Appointed new members of Executive Team to prepare for growth in late-stage clinical development and commercialization Cash balance of $395.9 million positions company with runway through the third quarter of 2024

      8/5/22 7:00:00 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia

      Registrational Phase 2 data demonstrate olutasidenib's potential as a market-leading, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor for the treatment of relapsed or refractory acute myeloid leukemiaFDA has accepted Forma's NDA for olutasidenib, with a PDUFA target action date of February 15, 2023Forma to receive an upfront payment of $2.0 million and is eligible to receive an additional $17.5 million upon the achievement of certain near-term regulatory, approval, and first commercial sale milestones, as well as potential future development and commercial milestone payments of $215.5 million and tiered royalties in the low-teens to mid-thirtiesIf approved, olutasidenib would be Ri

      8/2/22 4:01:00 PM ET
      $FMTX
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care